)
Samsung Life Insurance (032830) investor relations material
Samsung Life Insurance Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
9M 2026 consolidated net profit rose 26.9% YoY to KRW2,686bn, supported by investment-profit growth of 40.0%; insurance service results declined 2.8%.
CSM was KRW14.3tn at September-end, up KRW1.1tn YTD; K-ICS was 209%.
Separate financial statements reported 9M net income of ₩2.79T versus ₩2.23T in the retrospectively restated prior period; total comprehensive income was ₩59.27T, including ₩56.48T of after-tax OCI.
Financial highlights
9M investment profits increased 40.0% YoY to KRW2,399bn; Q3 investment profits fell 21.9% YoY to KRW541bn.
9M insurance service results were KRW1,063bn, down 2.8% YoY; Q3 results rose 102.4% YoY to KRW529bn.
Q3 net profit was KRW792bn, up 9.6% YoY; 9M new business CSM increased 14.3% YoY to KRW2,626bn.
Expense variance improved 33% YoY; a favorable first-instance ordinary-wage ruling led to a KRW52bn write-back of retirement benefit provisions recognized in Q1.
Variable insurance hedge results stabilized after H1 volatility, recording a KRW12bn gain in Q3.
Outlook and guidance
A comprehensive Value-up roadmap, including progress toward a 50% shareholder-return ratio by 2028, was planned for communication by February or early 2027.
Overseas pretax earnings target is 20% or more within 10 years; expansion will focus on growth markets with selective investment discipline.
Q4 insurance service results remain difficult to estimate; updated claims and lapse experience may create CSM losses in some product segments.
Mid-term ESG targets include net-zero carbon neutrality by 2050 and eco-friendly finance of KRW20tn or more by 2030.
Strategic priorities include protection-oriented new business and CSM growth, improved ALM and investment returns, and expansion of senior living, healthcare and digital offerings.
- Profit rose 19.7% as CSM and health-led new business expanded.032830
Q4 2023 - H1 2026 net profit up 35.8% YoY to KRW 1.97T, strong capital, CSM, and diversified growth.032830
Q2 2026 - Q1 net income up 89.5%–90% YoY, CSM and health product sales surged, K-ICS ratio at 210%.032830
Q1 2026 - FY2025 net profit rose 9.3% to KRW 2.3T, with record CSM and DPS up 18%; strong 2026 growth targeted.032830
Q4 2025 - Net profit up 3.7% YoY, with strong capital, health CSM growth, and higher equity.032830
Q3 2025 - H1 2025 net profit up 1.9% to KRW 1.394T, KICS at 187%, assets KRW 319.1T, ESG AA.032830
Q2 2025 - Q3 net profit up 41.6% YoY, strong health insurance and capital, CSM at ₩13 trillion.032830
Q3 2024 - Net profit up 40.5% to KRW 1.37T in H1 2024; health CSM leads; 50% payout ratio targeted.032830
Q2 2024 - Q1 2025 net profit reached KRW 677.5B, assets KRW 318.9T, solvency margin 218.8%.032830
Q1 2025
)
)
)
)
)
)
)
)